Core Insights - Intellia Therapeutics reported a narrower loss of 83 cents per share for Q4 2025, compared to a loss of $1.27 per share in the same quarter last year, and better than the Zacks Consensus Estimate of a loss of 99 cents [1][7] - The company generated revenues of $23 million in Q4 2025, significantly exceeding the Zacks Consensus Estimate of $12 million, marking a 73.8% year-over-year increase driven by collaboration revenues [2][7] - Intellia's stock rose by 6.4% following the positive earnings report, with a 24% increase over the past six months, outperforming the industry average of 22.4% [3] Financial Performance - Research and development expenses for Q4 totaled $88.7 million, a decrease of 24.1% from the previous year, attributed to lower employee-related expenses and stock-based compensation [4] - General and administrative expenses increased by 2.2% year-over-year to $33.1 million [4] - For the full year 2025, Intellia reported revenues of $67.7 million, up from $57.9 million in 2024, with a loss of $3.81 per share, an improvement from a loss of $5.25 per share in the prior year [9] Cash Position - As of December 31, 2025, Intellia had cash, cash equivalents, and marketable securities totaling $605.1 million, down from $669.9 million as of September 30, 2025 [5] Pipeline Developments - Intellia is developing lonvo-z for hereditary angioedema (HAE), with top-line data expected by mid-2026 and a potential U.S. launch in the first half of 2027 [7][13] - The FDA lifted the clinical hold on the IND for the phase III study of nexiguran ziclumeran (nex-z), with enrollment expected to complete in the second half of 2026 [11][12] - Intellia is currently working with the FDA to resolve the clinical hold on the MAGNITUDE study for nex-z [12]

INTELLIA THERAPEUTICS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37766 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: ...

Intellia Therapeutics (NasdaqGM:NTLA) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsEdward Dulac - EVP and CFOJason Fredette - Vice President of Investor Relations and Corporate CommunicationsJohn Leonard - President and CEOLidiya Rizova - Associate, Equity ResearchNone - Company RepresentativeConference Call ParticipantsAlec Stranahan - Senior Analyst, Equity ResearchBrian Cheng - Executive Director and Senior Biotech AnalystJack Allen - Senior Research AnalystJonathan Miller - An ...

Intellia Therapeutics (NasdaqGM:NTLA) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsEdward Dulac - EVP and CFOJason Fredette - Vice President of Investor Relations and Corporate CommunicationsJohn Leonard - President and CEOLidiya Rizova - Associate, Equity ResearchNone - Company RepresentativeConference Call ParticipantsAlec Stranahan - Senior Analyst, Equity ResearchBrian Cheng - Executive Director and Senior Biotech AnalystJack Allen - Senior Research AnalystJonathan Miller - An ...

Intellia Therapeutics (NasdaqGM:NTLA) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Speaker11Hello, and welcome to Intellia Therapeutics' fourth quarter and full year 2025 conference call. My name is Drew, and I will be your conference operator today. Please be advised that today's call is being recorded. I will now turn the call over to Jason Fredette, Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed.Speaker4Thank you, operator. Hello, everyone. Earlier th ...

Exhibit 99.1 Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates CAMBRIDGE, Mass., Feb. 26, 2026 – Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the fourth quarter and year ended December 31, 2025. "2025 was a time of accomplishment and resiliency for Intellia as we pres ...

HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027Process underway to reactivate global sites for MAGNITUDE-2 Phase 3 clinical trial of nex-z in ATTRv-PN; enrollment completion expected in second half of 2026FDA engagement ongoing to resolve clinical hold on MAGNITUDE Phase 3 clinical trial of nex-z in ATTR-CM Ended 2025 with approximately $605 million in cash, cash equivalents and marketable securities; e ...

CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that management will be participating in the upcoming investor conferences: TD Cowen 46th Annual Health Care ConferenceDate: Tuesday, March 3, 2026Fireside Chat Time: 1:10 p.m. ETLocation: Boston, MA Leerink Global Healthcare ConferenceDate: Monday, March 9, 2026Fireside Chat Time: 8:40 a ...

Core Viewpoint - Intellia Therapeutics, Inc. is set to host a conference call on February 26, 2026, to discuss its fourth quarter and full-year 2025 financial results and business updates [1]. Group 1: Company Overview - Intellia Therapeutics is a leading clinical-stage gene editing company focused on CRISPR-based therapies aimed at revolutionizing medicine [3]. - The company aims to develop novel, first-in-class medicines that address significant unmet medical needs and advance treatment paradigms for patients [3]. - Intellia is expanding its CRISPR-based platform with novel editing and delivery technologies to harness the full potential of gene editing [3]. Group 2: Conference Call Details - The conference call will take place at 8 a.m. ET on February 26, 2026 [1]. - U.S. callers can join the teleconference by dialing 1-833-316-0545, while international callers should dial 1-412-317-5726 [2]. - A replay of the call will be available for approximately 90 days on the Events page of Intellia's website [2].

Group 1 - Intellia Therapeutics, Inc. (NASDAQ:NTLA) is recognized as one of the best innovative stocks to buy according to Wall Street analysts, with H.C. Wainwright reiterating a Buy rating and increasing the price target to $25 from $15 following the removal of a clinical hold on the MAGNITUDE-2 study [1][3]. - The updated protocol for the MAGNITUDE-2 study raises the target enrollment to approximately 60 patients from the original 50, indicating a focus on improving risk mitigation and data comprehension rather than discontinuing the drug [3]. - The safety incidents that led to the clinical hold were rare, with two Grade 4/5 liver incidents, one of which was fatal, occurring in about 450 treated patients, representing less than 0.5% of the group [3]. Group 2 - Intellia Therapeutics is a biotech company specializing in CRISPR-Cas9 gene-editing technology, developing advanced treatments for both in vivo and ex vivo applications, with its primary initiative, NTLA-2001, targeting transthyretin amyloidosis, an incurable disease [4].